Last reviewed · How we verify
NCT03754361: URG-APD
The Study of Efficacy and Safety of Automated PD in Urgent Start Dialysis
NA trial testing automated peritoneal dialysis in ESRD in 34 participants. Terminated before completion.
31 July 2022
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 34 |
| Start date | 1 January 2019 |
| Primary completion | 31 July 2022 |
| Estimated completion | 28 December 2022 |
| Sites | 5 locations across China |
Drugs / interventions tested
- automated peritoneal dialysis
- IHD
Conditions studied
- ESRD — all drugs for ESRD →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 75, any sex, with ESRD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center, controlled clinical trial study. The purpose of this study is to examine the efficacy and safety of automated peritoneal dialysis as compared with intermittent haemodialysis for ESRD patients with indications for urgent start dialysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03754361
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ESRD
Currently open trials in the same condition.
- NCT06913647 — Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis · Phase 2 · recruiting
- NCT06366230 — Adding Urea to the Final Dialysis Fluid · Phase 1, PHASE2 · recruiting
- NCT05339139 — SAfety of Regional Citrate Anticoagulation (SARCA Study) · Phase 3 · recruiting
- NCT05434325 — TESTING -ON Post-Trial ObservatioNal Cohort Study · recruiting
- NCT05309785 — Safety and Efficacy of Canagliflozin in Advanced CKD · Phase 4 · active not recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03754361 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 8 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03754361.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing